GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

Biotech has been hard hit, as one might expect, leaving many names in bargain territory. Learn why there are opportunities ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Emergn is an organisation focused on improving product management expertise within organisations. First launched in September ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

Tariffs will already impact FTSE 100 constituent Convatec (CTC), which generates 40 per cent of its sales in the US. Most of its seven manufacturing sites are outside America, with key plants in ...